August 6, 2015

RANDOX LABORATORIES LIMITED  
PAULINE ARMSTRONG  
QA/RA MANAGER  
55 DIAMOND ROAD  
CRUMLIN BT29 4QY, GREAT BRITAIN

Re: K150819 Trade/Device Name: Triglycerides (TRIGS) Regulation Number: 21 CFR 862.1705 Regulation Name: Triglyceride test system Regulatory Class: Class I, meets the limitation of exemption 21 CFR §862.9(c)(4) Product Code: CDT Dated: June 18, 2015 Received: June 22, 2015

Dear Pauline Armstrong:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Courtney H. Lias -S

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

<table><tr><td>DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use</td><td>Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.</td></tr><tr><td>510(k) Number (if known)</td><td></td></tr><tr><td colspan="2">K150819</td></tr><tr><td colspan="2">Device Name Triglycerides (TRIGS)</td></tr></table>

Indications for Use (Describe)

For the quantitative in vitro determination of Triglycerides in serum. Triglyceride measurements are used in the diagnosis and treatment of diseases involving lipid metabolism and various endocrine disorders e.g Diabetes mellitus, nephrosis and liver obstruction

This in vitro diagnostic device is intended for prescription use only.

# FOR FDA USE ONLY

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services   
Food and Drug Administration Office   
of Chief Information Officer   
Paperwork Reduction Act (PRA) Staff   
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and  person is not required to respond to,  collection of ainformation unless it displays  currently valid OMB number."

510(K) SUMMARY, TRIGLYCERIDES ASSAY

# 1. SAFETY AND EFFECTIVENESS AS REQUIRED BY 21 CFR 807.92 STATEMENT

This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirement 21 CFR 807.92.

# 2. SUBMITTER NAME AND ADDRESS

Name: Dr Pauline Armstrong

Address: Randox Laboratories Limited 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom.

Telephone: $+ 4 4$ (0) 28 9442 2413 Fax: $+ 4 4$ (0) 28 9445 2912 E-mail: Pauline.Armstrong@randox.com

Date of Summary Preparation: July 9, 2015

# 3. 510k NUMBER, DEVICE PROPRIETARY NAME, COMMON NAME, PURPOSE FOR SUBMISSION, REGULATORY CLASSIFCATION, PANEL, PRODUCT CODE AND 21 CFR NUMBER

510k No: K150819

Device Proprietary Name: Triglycerides (TRIGS)

Common Name: Triglycerides

Purpose for Submission: New Device

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Regulation Name</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>CDT</td><td rowspan=1 colspan=1>Triglycerides testsystem</td><td rowspan=1 colspan=1>I, meets thelimitations toexemptions 21CFR §862.9 (c)(4)</td><td rowspan=1 colspan=1>21 CFR862.1705</td><td rowspan=1 colspan=1>ClinicalChemistry(75)</td></tr></table>

# 4. PREDICATE DEVICE PROPRIETARY NAMES AND 510 (k) NUMBERS

Predicate Device Proprietary Name:

Randox Laboratories Ltd, Triglycerides reagent

510 (k) Number: K923508

# 5. INTENDED USE

For the quantitative in vitro determination of Triglycerides in serum. Triglyceride measurements are used in the diagnosis and treatment of diseases involving lipid metabolism and various endocrine disorders e.g Diabetes mellitus, nephrosis and liver obstruction

This in vitro diagnostic device is intended for prescription use only.

# 6. DEVICE DESCRIPTION

The Randox Triglycerides kit assay consists of ready to use reagent solutions.

CATALOGUE NUMBER: TR8332

R1. Enzyme Reagent 4 x 20 ml

# REAGENT COMPOSITION

<table><tr><td>Contents</td><td>Initial Concentrations</td></tr><tr><td>R1. Enzyme Reagent</td><td></td></tr><tr><td>Pipes buffer</td><td>38.7 mmol/L, pH 7.5</td></tr><tr><td>4-chloro-phenol</td><td>3.4 mmol/L</td></tr><tr><td>Magnesium ions</td><td>16.9 mmol/L</td></tr><tr><td>4- aminophenazone</td><td>0.25 mmol/L</td></tr><tr><td>ATP</td><td>1.2 mmol/L</td></tr><tr><td>Lipases</td><td>≥ 10 u/mL</td></tr><tr><td>Glycerol kinase</td><td>≥ 0.4 u/mL</td></tr><tr><td>Glycerol-3-phosphate oxidase</td><td>≥ 1.5 u/mL</td></tr><tr><td>Peroxidase</td><td>≥ 0.5 u/mL</td></tr><tr><td>Sodium azide</td><td>0.05%</td></tr></table>

# MATERIALS REQUIRED BUT NOT PROVIDED

Randox Assayed Multisera Level 2 (Cat. No. HN 1530) and   
Level 3 (Cat. No. HE 1532); 510(k) # k942458   
Randox Calibration Serum Level 3 (Cat. No. CAL 2351); 510(k) # k053153   
RX series Saline (Cat. No. SA 8396)

# 7. PREDICATE DEVICE COMPARISON TABLE

Table 1 Comparison of Triglycerides test system for the RX Daytona plus to predicate device   

<table><tr><td rowspan=1 colspan=1>CHARACTERISTICS</td><td rowspan=1 colspan=1>Randox Triglycerides Assay forRX daytona plus(New Device)</td><td rowspan=1 colspan=1>RandoxTriglyceride Assay(K923508)(Predicate Device)</td></tr><tr><td rowspan=1 colspan=2>Similarities</td><td></td></tr><tr><td rowspan=1 colspan=1>INTENDED USE</td><td rowspan=1 colspan=1>For the quantitative in vitro determination ofTriglycerides in serum. Triglyceridemeasurements are used in the diagnosis andtreatment of diseases involving lipidmetabolism and various endocrine disorderse.g Diabetes mellitus, nephrosis and liverobstruction</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ASSAY PROTOCOL</td><td rowspan=1 colspan=1>Colorimetric Method</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>STORAGE(UNOPENED)</td><td rowspan=1 colspan=1>Reagents are stable up to the expiry datewhen stored unopened at +2 to +8°C</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CONTROLFREQUENCY</td><td rowspan=1 colspan=1>Randox assayed human multisera Level 2 &amp; 3Two levels of control should be assayed atleast once a day</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CALIBRATIONFREQUENCY</td><td rowspan=1 colspan=1>Every 28 days, with a change ofreagent lot or as indicated by quality controlprocedures.</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="5">Differences</td></tr><tr><td rowspan="5">REAGENT Pipes buffer COMPOSITION</td><td rowspan="10">R1. Enzyme Reagent ATP</td><td colspan="3">R1a. Buffer</td></tr><tr><td>38.7 mmol/L,</td><td>Pipes Buffer 4-chloro-phenol</td><td>40 mmol/l, pH 7.5 5.0 mmol/I</td></tr><tr><td>H 7.5 4-chloro-phenol 3.4 mmol/L</td><td>Magnesium-ions</td><td>5.0 mmol/l</td></tr><tr><td>Magnesium ions 16.9 mmol/L 4- aminophenazone 0.25 mmol/L</td><td>R1b. Enzyme Reagent 4-aminophenazone 0.4 mmol/I</td><td></td></tr><tr><td>Lipases</td><td>ATP</td><td>1.0 mmol/l</td></tr><tr><td>≥ 10 u/mL</td><td>1.2 mmol/L Lipases</td><td></td></tr><tr><td>≥ 0.4 u/mL</td><td></td><td>≥150 U/ml</td></tr><tr><td>Glycerol kinase</td><td>Glycerol-kinase</td><td>≥ 0.4 U/ml</td></tr><tr><td>Glycerol-3-phosphate oxidase ≥ 1.5 u/mL</td><td>Glycerol-3-phosphate</td><td></td></tr><tr><td>Peroxidase ≥ 0.5 u/mL Sodium azide 0.05%</td><td>oxidase</td><td>≥ 1.5 U/ml</td></tr><tr><td>TEST RANGE</td><td>12.4 - 1000mg/dl</td><td></td><td>Peroxidase ≥ 0.5 U/ml</td></tr><tr><td rowspan="2">SAMPLE TYPE</td><td></td><td></td><td>11.5 - 1133mg/dl</td></tr><tr><td>Serum</td><td></td><td>Serum, heparinized plasma and EDTA plasma samples are suitable.</td></tr></table>

# 8. TEST PRINCIPLE

The Triglycerides is determined after enzymatic hydrolysis and oxidation. The indicator quinoneimine is formed from hydrogen peroxide and 4-aminoantipyrine in the presence of phenol and peroxidase and read at 510nm.

![](images/7cab0a2ed3b297b8407d249fba3a7e3f3f737b35adaf5950c6fcdee6e61b49e7.jpg)

# 9. PERFORMANCE CHARACTERISTICS

Analytical performance:

# a. Precision/Reproducibility:

Precision was evaluated consistent with C.L.S.I documents EP5-A2 Precision studies were performed by two operators on two RX Daytona plus systems using serum based control material and unaltered human serum samples that were spiked with triglycerides concentrations or diluted to achieve concentrations based on established ranges $\ k < 1 5 0 \ m { \mathfrak { g } } / { \mathrm { d } } |$ normal triglycerides level ; $1 5 0 - 1 9 9 \mathrm { m g / d } |$ borderline high triglycerides level; 200 – 499 mg/dl high triglycerides level and $\geq 5 0 0 { \mathrm { ~ m g / d } } |$ very high triglycerides level. Testing was conducted for two reagent lots of triglycerides, one lot on each RX Daytona plus system, twice per day for 20 non-consecutive days. Two replicates per run were performed for each sample. No assay re-calibrations were required throughout the duration of the study. The results are summarized in the following tables.

Table 2 Precision Summary   

<table><tr><td rowspan=1 colspan=3>System: RX Daytona Plus</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Among Run</td><td rowspan=1 colspan=2>Among Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>MethodLot 1</td><td rowspan=1 colspan=1>Product</td><td rowspan=1 colspan=1>MEAN(mg/dl)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>$Cv</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>SensitivityPool</td><td rowspan=1 colspan=1>13.3</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>13.4</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>SerumPool 1</td><td rowspan=1 colspan=1>96.4</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>QC 1</td><td rowspan=1 colspan=1>96.5</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>PatientPool 2</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.65</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>PatientPool 1</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>2.65</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.65</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>SerumPool 2</td><td rowspan=1 colspan=1>237</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>7.08</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>CAL</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>QC 2</td><td rowspan=1 colspan=1>259</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>SerumPool 3</td><td rowspan=1 colspan=1>326</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>1.6</td></tr></table>

<table><tr><td rowspan=1 colspan=3>System: RX Daytona Plus</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Among Run</td><td rowspan=1 colspan=2>Among Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>MethodLot 2</td><td rowspan=1 colspan=1>Product</td><td rowspan=1 colspan=1>MEAN(mg/dl)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>cv(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>SensitivityPool</td><td rowspan=1 colspan=1>17.7</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>11.6</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>801UNQC 2</td><td rowspan=1 colspan=1>97.3</td><td rowspan=1 colspan=1>2.65</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>SerumPool 1</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>2.65</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.65</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>832UECAL</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>5.31</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>7.08</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>SerumPool 2</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>6.19</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>587UEQC 3</td><td rowspan=1 colspan=1>265</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.65</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>6.19</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>SerumPool 3</td><td rowspan=1 colspan=1>326</td><td rowspan=1 colspan=1>7.08</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>7.08</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>7.08</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>SerumPool 4</td><td rowspan=1 colspan=1>514</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>7.96</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>14.2</td><td rowspan=1 colspan=1>2.8</td></tr></table>

# b. Linearity/assay reportable range:

Linearity studies have been carried out in accordance with C.L.S.I. standard EP6-A. Linearity studies were performed at 11 levels to determine the analytical range of an assay - that is the range where the reported result is a linear function to the analyte concentration (or where deviation from linearity is less than $5 \%$ ).

The linearity samples were prepared at 11 levels. The sponsor set a range from 12.4 mg/dl analyte concentration up to a high concentration approximately 1000mg/dl using low and high serum pools. The low and high pools were mixed to make nine intermediate levels. Each level was run in replicates of five on two lots of Triglycerides reagent on one RX Daytona plus system. The observed values were compared to the expected values; the results are summarized in the following table:

![](images/e321e1c007f5df54f3f76194dc118157573954ae6bade6d7569f97744fc94a42.jpg)  
Table 3 Linearity Summary including Regression equation and correlation co-efficient.

<table><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.96</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>3.30</td></tr><tr><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>1.000</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>Reportable Range</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>1000 mg/dl</td><td rowspan=1 colspan=1>12.4  1000 mg/dl</td></tr></table>

The low end of the reportable assay range is based on the Limit of Quantitation.   
The high end of the reportable assay range is based on the linearity.

The Rx Daytona Plus analyzer has an auto-dilution feature that is automatically activated when measuring samples $> 1 0 0 0 ~ \mathrm { m g / d L }$ , which are diluted and remeasured to obtain values within the measuring range.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Refer to K053153 Calibrator and K942458 Control for Triglycerides.

Randox Calibration Serum Level 3 is traceable to Triglycerides reference method ID-GC/MS.

# d. Detection limit:

Sensitivity studies have been carried out in accordance with C.L.S.I. guideline EP17-A2 ‘Evaluation of detection capability for clinical laboratory measurement procedures; Approved Guideline Second Edition’. A Limit of Blank (L.o.B.), a Limit of Detection (L.o.D.) and a Limit of Quantification were performed on two lots of reagents tested by two operators on one RX Daytona Plus system.

The Limit of Detection (LoD) for Triglycerides on the RX Daytona Plus is 3.96 mg/dl based on 240 determinations, with 4 low level samples.

The Limit of Blank (LoB) is 2.65 mg/dl.

The Limit of Quantitation (LoQ) is 12.4 mg/dl as determined by the lowest concentration at which precision is still met.

# e. Analytical Specificity:

Interference studies have been carried out in accordance with C.L.S.I. guideline EP7-A2 ‘Interference testing in clinical chemistry; Approved Guideline Second Edition’ The effects of potential interferents were determined by calculating the mean value of the spiked interferent with the corresponding control solution. The spiked sample results were compared to control samples prepared without the potential interferents.

# Acceptance Criteria:

The criteria for no significant interference is recovery within $\pm 1 0 \%$ of the initial value of Triglycerides concentration of 150mg/dL and 496mg/dL

Haemoglobin No significant interference up to 750mg/dL Total Bilirubin No significant interference up to 60mg/dL

Conjugate Bilirubin No significant interference up to 60mg/dL Ascorbic Acid No significant interference up to 3.0mg/dL f. Method comparison with predicate device:

Correlation studies were carried out in accordance with C.L.S.I. guideline EP9-A2 ‘Method Comparison and Bias Estimation Using Patient Samples: Approved Guideline – Second Edition’.

109 serum patient samples spanning the range 14.2 to 986 mg/dl were tested by two operators on two lots of Triglycerides reagent on one RX Daytona plus analyzer and the predicate device tested on one RX Imola system across 3 working days with each sample tested in singlicate. The test method was compared to the predicate device and the following linear regression equation was obtained:

$\ Y = 0 . 9 7 x + 1 . 2 2$ Correlation coefficient of $\mathsf { r } = 0 . 9 9 9$

# Expected values/Reference range:

The NCEP (American National Cholesterol Education Program) has established the following classification for triglyceride levels according to the risk of developing coronary heart diseases:

Table 4 Reference Ranges   

<table><tr><td>Analyte</td><td>Expected Values</td></tr><tr><td>Triglycerides (1)</td><td>Normal &lt; 150 mg/dl Borderline-high 150 - 199 mg/dl High 200 - 499 mg/dl Very High ≥ 500 mg/dl</td></tr></table>

1. ATP III Guidelines At-A-Glance Quick Desk Reference, National Cholesterol Education Program, National Institute of Health Publication No. 01-3305, May 2001.

# 10. CONCLUSION

Testing results indicate that the proposed device is substantially equivalent to the predicate device.